Secukinumab
Interleukin Inhibitors
Sold as COSENTYX
- Drug class
- Interleukin Inhibitors
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 15
Overview
Secukinumab is an active pharmaceutical ingredient in the Interleukin Inhibitors group (L04AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 8 | April 17, 2026 |
| CA Canada | Health Canada | 6 | September 24, 2025 |
| EU European Union | EMA | 1 | December 18, 2025 |
GBUnited Kingdom· MHRA
8 products
Uses
Paediatric plaque psoriasis Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. 1). 1).
How to take
CACanada· Health Canada
6 products
How to take
4 Geriatrics 2024-04 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ..........................................................................................
2 TABLE OF CONTENTS ............................................................................................................ 2 Part 1: Health Professional Information ................................................................................
5 1. Indications ................................................................................................................ 1 Pediatrics................................................................................................................
2 Geriatrics ................................................................................................................ 6 2. Contraindications ......................................................................................................
EUEuropean Union· EMA
1 product
Uses
Paediatric plaque psoriasis Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. 1). 1).
How to take
Drug interactions
Known interactions involving Secukinumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB001011205 · revised April 17, 2026
- [2]Health Canada (DPD) · 02438062 · revised July 31, 2025
- [3]European Medicines Agency · EMEA/H/C/003729 · revised December 18, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.